MCID: EBL001
MIFTS: 44

Ebola Hemorrhagic Fever

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Ebola Hemorrhagic Fever

MalaCards integrated aliases for Ebola Hemorrhagic Fever:

Name: Ebola Hemorrhagic Fever 12 59 15
Ebola Virus Disease 12 76 53 59 3
Hemorrhagic Fever, Ebola 44 73
Ebola Fever 59
Ehf 59

Characteristics:

Orphanet epidemiological data:

59
ebola hemorrhagic fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Ebola Hemorrhagic Fever

Disease Ontology : 12 A viral infectious disease that is a hemorrhagic fever, has material basis in Zaire ebolavirus, has material basis in Sudan ebolavirus, has material basis in Cote d'Ivoire ebolavirus, or has material basis in Bundibugyo ebolavirus, which are transmitted by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has symptom fever, has symptom headache, has symptom joint pain, has symptom muscle aches, has symptom sore throat, has symptom weakness, has symptom diarrhea, has symptom vomiting, has symptom stomach pain, has symptom rash, has symptom red eyes, has symptom hiccups, and has symptom internal and external bleeding.

MalaCards based summary : Ebola Hemorrhagic Fever, also known as ebola virus disease, is related to marburg hemorrhagic fever and leprosy 3, and has symptoms including fever and pruritus. An important gene associated with Ebola Hemorrhagic Fever is F5 (Coagulation Factor V). The drugs Vaccines and Loperamide have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and eye, and related phenotypes are renal insufficiency and proteinuria

Wikipedia : 76 Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola, is a viral... more...

Related Diseases for Ebola Hemorrhagic Fever

Diseases related to Ebola Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 marburg hemorrhagic fever 11.1
2 leprosy 3 10.9
3 allergic urticaria 10.9
4 neurodermatitis 10.9
5 hemorrhagic fever 10.8
6 lassa fever 10.0
7 venezuelan equine encephalitis 9.9
8 encephalitis 9.9
9 stomatitis 9.9
10 endotheliitis 9.9
11 meningoencephalitis 9.8
12 hemopericardium 9.8
13 pericardial effusion 9.8
14 myocarditis 9.8
15 disseminated intravascular coagulation 9.6 F5 MB

Graphical network of the top 20 diseases related to Ebola Hemorrhagic Fever:



Diseases related to Ebola Hemorrhagic Fever

Symptoms & Phenotypes for Ebola Hemorrhagic Fever

Human phenotypes related to Ebola Hemorrhagic Fever:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
2 proteinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000093
3 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
4 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
5 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
6 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
7 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
8 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
9 cardiac arrest 59 32 frequent (33%) Frequent (79-30%) HP:0001695
10 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
11 leukopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001882
12 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
13 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
14 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
15 restrictive ventilatory defect 59 32 frequent (33%) Frequent (79-30%) HP:0002091
16 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
17 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
18 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
19 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0006554
20 chemosis 59 32 frequent (33%) Frequent (79-30%) HP:0012375
21 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
22 macule 59 32 occasional (7.5%) Occasional (29-5%) HP:0012733
23 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
24 metrorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100608
25 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
26 recurrent pharyngitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100776
27 abnormal bleeding 59 Occasional (29-5%)

UMLS symptoms related to Ebola Hemorrhagic Fever:


fever, pruritus

GenomeRNAi Phenotypes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.62 F5 NPC1

Drugs & Therapeutics for Ebola Hemorrhagic Fever

Drugs for Ebola Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
2
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
3 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
4 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
5 Anti-Infective Agents Phase 2, Phase 3,Phase 1
6 Iron-Dextran Complex Phase 3,Phase 2,Phase 1
7 Krestin Phase 3,Phase 2,Phase 1
8
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 447043
9
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
10
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
11
Angiotensin II Approved, Investigational Phase 1, Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12
Coal tar Approved Phase 1, Phase 2,Phase 2 8007-45-2
13
Lumefantrine Approved Phase 2 82186-77-4 6437380
14
Artemether Approved Phase 2 71963-77-4 119380 68911
15 Atorvastatin Calcium Phase 1, Phase 2 134523-03-8
16
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
17 Angiogenesis Inhibitors Phase 1, Phase 2
18 Angiogenesis Modulating Agents Phase 1, Phase 2
19 Angiotensin II Type 1 Receptor Blockers Phase 1, Phase 2
20 Angiotensin Receptor Antagonists Phase 1, Phase 2
21 Angiotensinogen Phase 1, Phase 2
22 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2,Phase 2
23 Hypolipidemic Agents Phase 1, Phase 2,Phase 2
24 Antihypertensive Agents Phase 1, Phase 2
25 Anticholesteremic Agents Phase 1, Phase 2,Phase 2
26 Lipid Regulating Agents Phase 1, Phase 2,Phase 2
27 Protein Kinase Inhibitors Phase 1, Phase 2
28 Antimetabolites Phase 1, Phase 2,Phase 2
29 Calcium, Dietary Phase 1, Phase 2
30 Disinfectants Phase 2
31 Antibiotics, Antitubercular Phase 2,Phase 1
32 Vitamins Phase 2
33 Antidiarrheals Phase 2
34 Artemether-lumefantrine combination Phase 2
35 Antiviral Agents Phase 2,Phase 1
36 Antibodies Phase 1, Phase 2
37 Immunoglobulins Phase 1, Phase 2
38 Anti-Inflammatory Agents Phase 2
39 Dermatologic Agents Phase 1, Phase 2
40 Keratolytic Agents Phase 1, Phase 2
41 interferons Phase 1
42 Cathartics Phase 1
43 Adjuvants, Immunologic Phase 1
44 Gastrointestinal Agents Phase 1
45 Poly I-C Phase 1
46 Poly ICLC Phase 1
47 Interferon Inducers Phase 1
48 Laxatives Phase 1
49 Protective Agents Phase 1
50 Radiation-Protective Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Recruiting NCT03072030 Phase 4
2 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
3 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
4 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
5 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
6 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
7 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
8 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
9 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Active, not recruiting NCT03161366 Phase 3
10 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
11 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
12 Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen Unknown status NCT02739477 Phase 2 Favipiravir
13 A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Completed NCT02575456 Phase 2
14 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults Completed NCT02485301 Phase 2 Placebo
15 Efficacy of Favipiravir Against Ebola (JIKI) Completed NCT02329054 Phase 2 Favipiravir
16 Efficacy of Favipiravir Against Severe Ebola Virus Disease Completed NCT02662855 Phase 2 Favipiravir
17 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Completed NCT02548078 Phase 2
18 A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland Completed NCT02289027 Phase 1, Phase 2
19 A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults Completed NCT02416453 Phase 2
20 VSV-ZEBOV Geneva Vaccine Trial Completed NCT02287480 Phase 1, Phase 2
21 Partnership for Research on Ebola VACcinations Recruiting NCT02876328 Phase 2
22 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Recruiting NCT03031912 Phase 2
23 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Recruiting NCT02818582 Phase 2 GS-5734
24 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Recruiting NCT03333538 Phase 1, Phase 2
25 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
26 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Active, not recruiting NCT02344407 Phase 2
27 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults Active, not recruiting NCT02564523 Phase 2
28 Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Active, not recruiting NCT02598388 Phase 2
29 Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure Enrolling by invitation NCT02788227 Phase 2 rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
30 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Suspended NCT02363322 Phase 1, Phase 2 ZMApp
31 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn NCT02271347 Phase 2 CMX001
32 A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. Unknown status NCT02296983 Phase 1
33 A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. Completed NCT02326194 Phase 1
34 Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Completed NCT02718469 Phase 1
35 Evaluating an Ebola and a Marburg Vaccine in Uganda Completed NCT00997607 Phase 1
36 A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo Completed NCT02240875 Phase 1
37 A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization Completed NCT02533791 Phase 1
38 Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda Completed NCT02354404 Phase 1
39 Phase 1 Trial of Ebola Vaccine in Mali Completed NCT02267109 Phase 1
40 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) Completed NCT02283099 Phase 1
41 Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects Completed NCT02370589 Phase 1
42 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine Completed NCT02374385 Phase 1
43 A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. Completed NCT02401373 Phase 1
44 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) Completed NCT02280408 Phase 1
45 A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Completed NCT02495246 Phase 1
46 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) Completed NCT02314923 Phase 1
47 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) Completed NCT02269423 Phase 1
48 Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) Completed NCT02368119 Phase 1
49 Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination Completed NCT02485912 Phase 1
50 Experimental Ebola Vaccine Trial Completed NCT00072605 Phase 1 VRC-EBODNA012-00-VP

Search NIH Clinical Center for Ebola Hemorrhagic Fever

Cochrane evidence based reviews: hemorrhagic fever, ebola

Genetic Tests for Ebola Hemorrhagic Fever

Anatomical Context for Ebola Hemorrhagic Fever

MalaCards organs/tissues related to Ebola Hemorrhagic Fever:

41
Liver, Kidney, Eye, Skin, Testes, Endothelial, Monocytes

Publications for Ebola Hemorrhagic Fever

Articles related to Ebola Hemorrhagic Fever:

(show top 50) (show all 85)
# Title Authors Year
1
Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. ( 28854896 )
2017
2
Knowledge, Attitudes, and Practices among Members of Households Actively Monitored or Quarantined to Prevent Transmission of Ebola Virus Disease - Margibi County, Liberia: February-March 2015. ( 28748776 )
2017
3
Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report. ( 27043004 )
2016
4
An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. ( 27402779 )
2016
5
Improving health care workers' protection against infection of Ebola hemorrhagic fever through video surveillance. ( 27112368 )
2016
6
Control of Ebola hemorrhagic fever: vaccine development and our Ebola project in Sierra Leone. ( 28484179 )
2016
7
Cardiac MRI Findings Suggest Myocarditis in Severe Ebola Virus Disease. ( 27544899 )
2016
8
Updates in diagnosis and management of Ebola hemorrhagic fever. ( 28163730 )
2016
9
Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. ( 26908739 )
2016
10
Ebola hemorrhagic fever under scope, view of knowledge, attitude and practice from rural Sudan in 2015. ( 27396613 )
2016
11
Knowledge regarding Ebola Hemorrhagic Fever among private dental practitioners in Tricity, India: A cross-sectional questionnaire study. ( 25838631 )
2015
12
Monitoring of Persons with Risk for Exposure to Ebola Virus Disease - United States, November 3, 2014-March 8, 2015. ( 26135588 )
2015
13
Knowledge regarding Ebola Hemorrhagic Fever among private dental practitioners. ( 26759520 )
2015
14
Ebola hemorrhagic fever outbreaks: strategies for effective epidemic management, containment and control. ( 25892315 )
2015
15
YouTube videos as a source of medical information during the Ebola hemorrhagic fever epidemic. ( 26322263 )
2015
16
Ebola Hemorrhagic Fever as a Public Health Emergency of International Concern; a Review Article. ( 26512362 )
2015
17
Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa. ( 26171669 )
2015
18
Ebola hemorrhagic Fever and the current state of vaccine development. ( 25562048 )
2014
19
Ebola hemorrhagic Fever: genetic biomarkers and vaccine development. ( 25340986 )
2014
20
Ebola hemorrhagic fever: case fatality rate 90%? ( 25438402 )
2014
21
Ebola hemorrhagic Fever. ( 25344714 )
2014
22
Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. ( 25359852 )
2014
23
Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. ( 24526742 )
2014
24
Ebola hemorrhagic Fever in 2014: the tale of an evolving epidemic. ( 25133433 )
2014
25
On the mathematical analysis of Ebola hemorrhagic fever: deathly infection disease in West African countries. ( 25688348 )
2014
26
Surgical Infection Society Statement on Ebola Hemorrhagic Fever. ( 25313927 )
2014
27
Ebola hemorrhagic fever: current outbreak and progress in finding a cure. ( 25392051 )
2014
28
Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives. ( 25694097 )
2014
29
Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever? ( 23638738 )
2013
30
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. ( 23045629 )
2013
31
Dead or alive: animal sampling during Ebola hemorrhagic fever outbreaks in humans. ( 22558004 )
2012
32
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. ( 22558378 )
2012
33
Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation. ( 21987740 )
2011
34
Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. ( 20587179 )
2010
35
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. ( 18385248 )
2008
36
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. ( 17940975 )
2007
37
Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. ( 17940976 )
2007
38
Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004. ( 17940949 )
2007
39
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. ( 17725815 )
2007
40
The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. ( 16113813 )
2005
41
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. ( 15896665 )
2005
42
Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. ( 15047846 )
2004
43
Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. ( 15569802 )
2004
44
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. ( 15357905 )
2004
45
Outbreak(s) of Ebola hemorrhagic fever, Congo and Gabon, October 2001 to July 2002. ( 12916393 )
2003
46
Ebola hemorrhagic fever and septic shock. ( 14639530 )
2003
47
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. ( 14633609 )
2003
48
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. ( 14633608 )
2003
49
Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. ( 14718087 )
2003
50
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. ( 14639531 )
2003

Variations for Ebola Hemorrhagic Fever

Expression for Ebola Hemorrhagic Fever

Search GEO for disease gene expression data for Ebola Hemorrhagic Fever.

Pathways for Ebola Hemorrhagic Fever

GO Terms for Ebola Hemorrhagic Fever

Sources for Ebola Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....